

Nebraska Chronic Renal Disease Program Pharmacy Update – January 2021



The Nebraska Chronic Renal Disease Program (CRD) is a client assistance program that provides payment for pharmaceutical and dialysis services to eligible Nebraska residents diagnosed with End-Stage Renal Disease (ESRD). It does not cover the costs related to any other illness.

Reimbursable Drug Formulary

The Program's Reimbursable Drug Formulary has been updated and will go into effect on February 1, 2021. Only drugs listed on the Formulary are reimbursable through the CRD Program. The new Formulary will be available on the Program's webpage: dhhs.ne.gov/renal after February 1, and is included with this fax.

This is a summary of the changes going into effect on February 1, 2021:

- Change Cinacalcet to generic only
- Add Eplerenone to list of covered drugs (generic only)
- Add Febuxostat to list of covered drugs (generic only)
- Add Magnesium Oxide to list of covered drugs (generic only)
- Add Virtcaps to list of covered brand multivitamins
- Remove Prorenal from list of covered brand multivitamins
- Add Patiromer (generic) / Veltassa (brand) to list of covered drugs
- Add Sodium Zirconium Cyclosilicate (generic) / Lokelma (brand) to list of covered drugs

It's important to note that all medications must be prescribed in order to be reimbursed and that only the listed vitamins – *specifically formulated for renal patients* – will be reimbursed.

The Program reimburses for generic drugs, unless there is not a generic available. Drugs not available in generic form are clearly indicated on the Formulary in the "Reimbursable" column. At this time, since the reimbursement rate for Sevelamer Carbonate (generic) / Renvela (brand) is the same, the Program will reimburse for both; however, this will be assessed annually and may change in the future.

Feel free to contact the Program at any time with questions or to check a drug's reimbursement price. The drug NDC number and quantity prescribed are needed to check pricing.